플루복사민

한글명:플루복사민

카스 번호54739-18-3

상품명:Fluvoxamine

CBNumberCB8468990

분자식C15H21F3N2O2

포뮬러 무게318.33

MOL 파일54739-18-3.mol

동의어(한글)

플루복사민

화학적 성질

녹는점	120-122.5°C
끓는 점	370.6±52.0 °C(Predicted)
밀도	1.16±0.1 g/cm3(Predicted)
저장 조건	Sealed in dry,2-8°C
용해도	클로로포름(난용성), DMSO (약간 용해됨), 메탄올 (약간 용해됨)
물리적 상태	기름
산도 계수 (pKa)	pKa 8.7 (Uncertain)
색상	무색
CAS 데이터베이스	54739-18-3(CAS DataBase Reference)
NIST	Fluvoxamine(54739-18-3)

그림문자(GHS)

그림문자(GHS)
신호 어

Danger
유해·위험 문구

H302：삼키면 유해함

H319：눈에 심한 자극을 일으킴

H331：흡입하면 유독함

H335：호흡 자극성을 일으킬 수 있음

H410：장기적 영향에 의해 수생생물에 매우 유독함
예방조치문구

P261：분진·흄·가스·미스트·증기·...·스프레이의 흡입을 피하시오.

P264：취급 후에는 손을 철저히 씻으시오.

P264：취급 후에는 손을 철저히 씻으시오.

P270：이 제품을 사용할 때에는 먹거나, 마시거나 흡연하지 마시오.

P271：옥외 또는 환기가 잘 되는 곳에서만 취급하시오.

P273：환경으로 배출하지 마시오.

P280：보호장갑/보호의/보안경/안면보호구를 착용하시오.

P301+P312：삼켜서 불편함을 느끼면 의료기관(의사)의 진찰을 받으시오.

P304+P340：흡입하면 신선한 공기가 있는 곳으로 옮기고 호흡하기 쉬운 자세로 안정을 취하시오.

P305+P351+P338：눈에 묻으면 몇 분간 물로 조심해서 씻으시오. 가능하면 콘택트렌즈를 제거하시오. 계속 씻으시오.

P311：의료기관(의사)의 진찰을 받으시오.

P321：(…) 처치를 하시오.

P330：입을 씻어내시오.

P391：누출물을 모으시오.

P403+P233：용기는 환기가 잘 되는 곳에 단단히 밀폐하여 저장하시오.

P405：밀봉하여 저장하시오.

P501：...에 내용물 / 용기를 폐기 하시오.

플루복사민 화학적 특성, 용도, 생산

화학적 성질
Colourless Oil
일반 설명
The E-isomer of fluvoxamine (Luvox) can fold after protonation to the β-arylamine–like grouping. Here,the “extra” hydrophobic group is aliphatic.
위험도
A poison.
Mechanism of action
Fluvoxamine is a highly selective inhibitor of 5-HT reuptake at the presynaptic membrane. Potency data from in vitro affinity studies suggest that fluvoxamine is less potent than the other SSRIs (e.g., paroxetine, sertraline, and citalopram). Its mechanism of action is similar to that of the other SSRIs. Fluvoxamine appears to have little or no effect on the reuptake of NE or dopamine. In vitro studies have demonstrated that fluvoxamine possesses virtually no affinity for other neuroreceptors. Its onset of action is similar to the other SSRIs (2–4 weeks).
Pharmacokinetics
Fluvoxamine is well absorbed, with a bioavailability of approximately 50%, probably because of first-pass metabolism. At steady-state doses, fluvoxamine demonstrates nonlinear pharmacokinetics over a dosage range of 100 to 300 mg/day, which results in higher plasma concentrations at higher doses than would be predicted by lower-dose kinetics (single dose, 15 hours; multiple dosing, 22 hours). Food does not significantly affect oral bioavailability. The mean apparent volume of distribution for fluvoxamine reflects its lipophilic nature, extensive tissue distribution, and protein binding. Fluvoxamine is distributed into breast milk. Fluvoxamine is preferentially metabolized by CYP2D6 in the liver by O-demethylation to its alcohol metabolite, which subsequently is oxidized to a carboxylic acid. Oxidative deamination and nine other metabolites have been identified, none of which shows significant pharmacological activity.
Clinical Use
Fluvoxamine is approved for use in obsessive-compulsive disorders.
부작용
The adverse effects for fluvoxamine include symptoms of drowsiness, nausea or vomiting, abdominal pain, tremors, sinus bradycardia, and mild anticholinergic symptoms. Toxic doses could produce seizures and severe bradycardia.
Drug interactions
In vitro studies have shown fluvoxamine to be a potent inhibitor of CYP1A2, to inhibit CYP3A4 and CYP2C19, and to weakly inhibit CYP2D6. The bioavailability of fluvoxamine is significantly decreased in smokers compared with nonsmokers, possibly because of induction of CYP1A metabolism of fluvoxamine. Therefore, interactions with drugs that inhibit CYP1A2 also should be considered (e.g., theophylline and caffeine).

플루복사민 준비 용품 및 원자재

플루복사민 공급 업체

플루복사민 관련 검색

Send Inquriy